Akebia Therapeutics Inc. (NASDAQ:AKBA) currently has a daily average trading volume of 2.87M but it saw 1687629 shares traded in last market. With a market cap of 309.13M USD, the company’s current market price of $1.47 came falling about -1.34 while comparing to the previous closing price of $1.49. In past 52 weeks, the stock remained buoying in the range of price level as high as $2.48 and as low as $0.78. In the recent trading on the day, stock has struck highest price mark of $1.465 while lowest mark touched by it was $1.54.
Taking a look at 20-day trading activity of Akebia Therapeutics Inc. (AKBA) gives us an average price of $1.3322, while its current price level is -40.73% below from 52-week high level whereas it is 88.44% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $1.2122 while that of 200 days or SMA-200 reads an average of $1.3252. A closer look into the stock’s movement over the week reveals that its volatility is standing at 5.77% during that period while stretching the period over a month that increases to 8.07%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 60.39 which implies that the stock is in neutral territory.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the BTIG Research which resumed the stock as “Buy” in its note to investors issued on November 29, 2023, recommending a price target of $4 for it. H.C. Wainwright upgraded its recommendation for the stock as a “Buy” from “Neutral” on August 28, 2023 while assigning a price target of $3.75. Piper Sandler issued its recommendations for the stock as it upgraded the price target for the stock in the range of between $2 and $4.
Over the week, AKBA’s stock price is moving 2.08% up while it is 0.00% when we observe its performance for the past one month. Year-to-date it is 18.55% up and over the past year, the stock is showing an upside performance of 16.67%.
The latest quarterly earnings report issued by the company reported quarterly earnings per share (EPS) of -0.08 beat the consensus estimate of -0.08 for the same. The company is expected to be releasing its next quarterly report in September, for which analysts forecasted an EPS of -0.06 while estimate for next year EPS is -0.24. In next quarter, company is expected to be making quarterly sales of $51.22M as analysts are expecting the sales for current fiscal year at $172M and seeing the company making $177.55M in sales next year. Moreover, analysts are in estimates of $44.51M for current-quarter revenue.
Currently, Akebia Therapeutics Inc.’s total number of outstanding shares is 210.29M. Company’s return on investment (ROI) stands at -63.51% and return on equity (ROE) at -554.87%. Stock’s beta reads 0.76. Stock has a price to sale or P/S ratio amounts to 1.77. Its return on asset (ROA) is -17.07% on average.
